Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.
Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.
复制标题
DOI：
10.1111/hiv.12217
复制
发表时间：
2018-01
期刊：
影响因子：
3
通讯作者：
(PENTA Steering Committee)
中科院分区：
文献类型：
--
作者：
Bamford A;Turkova A;Lyall H;Foster C;Klein N;Bastiaans D;Burger D;Bernadi S;Butler K;Chiappini E;Clayden P;Della Negra M;Giacomet V;Giaquinto C;Gibb D;Galli L;Hainaut M;Koros M;Marques L;Nastouli E;Niehues T;Noguera-Julian A;Rojo P;Rudin C;Scherpbier HJ;Tudor-Williams G;Welch SB;(PENTA Steering Committee)
2015年欧洲儿科艾滋病治疗网络（PENTA）指南提供了关于欧洲儿童HIV-1感染管理的实用建议，是对2009年发布的指南的更新。在过去的十年中，治疗的目标取得了显着进展，远远超出了短期发病率和死亡率的限制，以优化成年生活的健康状况，并尽量减少慢性HIV感染对免疫系统发育和健康的影响。此外，更需要提高认识和最大限度地减少长期药物毒性。对先前准则的主要更新包括：所有年龄段的抗逆转录病毒治疗（ART）适应症数量增加（考虑ART启动和其他临床适应症的更高CD 4阈值），修订一线和二线ART建议指南，包括最近可用的药物类别，扩大合并感染管理指南（包括肺结核、B型肝炎和C型肝炎），并进一步强调青少年在向成人服务过渡时的需要。有一个新的部分是关于目前ART药物开发的“管道”，一个全面的总结表，目前推荐的ART与剂量建议。PENTA和目前的美国和世界卫生组织的指导方针之间的差异突出和解释。
The 2015 Paediatric European Network for Treatment of AIDS (PENTA) guidelines provide practical recommendations on the management of HIV‐1 infection in children in Europe and are an update to those published in 2009. Aims of treatment have progressed significantly over the last decade, moving far beyond limitation of short‐term morbidity and mortality to optimizing health status for adult life and minimizing the impact of chronic HIV infection on immune system development and health in general. Additionally, there is a greater need for increased awareness and minimization of long‐term drug toxicity. The main updates to the previous guidelines include: an increase in the number of indications for antiretroviral therapy (ART) at all ages (higher CD4 thresholds for consideration of ART initiation and additional clinical indications), revised guidance on first‐ and second‐line ART recommendations, including more recently available drug classes, expanded guidance on management of coinfections (including tuberculosis, hepatitis B and hepatitis C) and additional emphasis on the needs of adolescents as they approach transition to adult services. There is a new section on the current ART ‘pipeline’ of drug development, a comprehensive summary table of currently recommended ART with dosing recommendations. Differences between PENTA and current US and World Health Organization guidelines are highlighted and explained.
登录
查看更多内容
影响因子：
5.2
作者：
Arpadi, Stephen;Shiau, Stephanie;Kuhn, Louise
通讯作者：
Kuhn, Louise
影响因子：
5.2
作者：
Bright-Thomas, R.;Nandwani, S.;Ormerod, L. P.
通讯作者：
Ormerod, L. P.
影响因子：
3
作者：
Briz, V.;Palladino, C.;Munoz-Fernandez, M. A.
通讯作者：
Munoz-Fernandez, M. A.
影响因子：
3.6
作者：
Briz, Veronica;Leon-Leal, Juan A.;Angeles Munoz-Fernandez, Ma
通讯作者：
Angeles Munoz-Fernandez, Ma
影响因子：
6.4
作者：
Avettand-Fenoel, Veronique;Blanche, Stephane;Buseyne, Florence
通讯作者：
Buseyne, Florence